Scales for Measuring Parkinsonism in Demented Patients

  • Carmen Rodriguez-Blazquez
  • Anna Sauerbier
  • K. Ray Chaudhuri
  • Pablo Martinez-MartinEmail author


The term “parkinsonism” refers to a syndrome combining motor symptoms such as bradykinesia, rigidity, tremor, and other clinical signs characteristic of Parkinson’s disease. A large range of these disorders can simultaneously express parkinsonism and dementia, although with variable occurrence particularly related to the onset of disease and expression of clinical symptoms. Therefore, motor and cognitive assessment in these conditions are relevant, for both clinical research and practice. Most of the rating scales applied in this situation are measures coming from the realm of the movement disorders, used for evaluation of Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, etc. Also, there are generic scales designed for assessment of motor state that may be useful in the appropriate context. Some of the most frequently used scales are reviewed in this chapter, with particular attention to their description and basic clinimetric properties.


Rating scales Assessment Parkinsonism Parkinson’s disease Progressive supranuclear palsy Multiple system atrophy Dementia Dementia with Lewy bodies Dementia associated with Parkinson’s disease Alzheimer’s disease 



Alzheimer’s disease


Dementia with Lewy bodies


Extrapyramidal Symptom Rating Scale


Functional Assessment Staging


International Cerebellar Ataxia Rating Scale


Movement Disorder Society-sponsored version of the UPDRS


Multiple system atrophy


Natural History and Neuroprotection in Parkinson Plus Syndromes – Parkinson Plus Scale


Parkinson’s disease


Dementia associated with Parkinson’s disease


Pyramidal and Extrapyramidal Scale


Postural instability gait difficulty


Palliative Care Outcome Scale-Parkinsonism Plus


Progressive supranuclear palsy


Progressive Supranuclear Palsy Rating Scale


Rating Scale for Gait Evaluation in Cognitive Deterioration


Scales for Outcomes in Parkinson’s Disease


Unified Multiple System Atrophy Rating Scale


Unified Parkinson’s Disease Rating Scale


  1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–92.PubMedCrossRefGoogle Scholar
  2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20:1255–63.PubMedCrossRefGoogle Scholar
  3. Aarsland D, Kvaløy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sørensen P, Marder K. The effect of age of onset of PD on risk of dementia. J Neurol. 2007;254:38–45.PubMedCrossRefGoogle Scholar
  4. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21:1123–30.PubMedCrossRefGoogle Scholar
  5. Ben Sassi S, Nabli F, Hentati E, Nahdi H, Trabelsi M, Ben Ayed H, et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:243–6.PubMedCrossRefGoogle Scholar
  6. Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:585–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017–22.PubMedCrossRefGoogle Scholar
  8. Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer’s disease. Neurology. 2003;61:954–8.PubMedCrossRefGoogle Scholar
  9. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247–65.PubMedCrossRefGoogle Scholar
  10. Cubo E, Stebbins GT, Golbe LI, Nieves AV, Leurgans S, Goetz CG, et al. Application of the unified Parkinson’s disease rating scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000;15:276–9.PubMedCrossRefGoogle Scholar
  11. De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001;62 Suppl 21:19–22.PubMedGoogle Scholar
  12. Dubois B, Pillon B, Sternic N, Lhermitte F, Agid Y. Age induced cognitive disturbances in Parkinson’s disease. Neurology. 1990;40:38–41.PubMedCrossRefGoogle Scholar
  13. Ellis RJ, Caligiuri M, Galasko D, Thal LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10:103–14.PubMedCrossRefGoogle Scholar
  14. Fahn S, Elton RL. UPDRS program members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson’s disease, vol. 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153–64.Google Scholar
  15. Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127:550–60.PubMedCrossRefGoogle Scholar
  16. Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the european MSA Study Group (EMSA SG). Mov Disord. 2006;21:179–86.PubMedCrossRefGoogle Scholar
  17. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22:41–7.PubMedCrossRefGoogle Scholar
  18. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–70.PubMedCrossRefGoogle Scholar
  19. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010;25:1190–4.PubMedCrossRefGoogle Scholar
  20. Goetz CG, Stebbins GT, LaPelle N, Huang J, Tilley BC. MDS-UPDRS non-English translation program. Mov Disord. 2012;27 Suppl 1:S96.Google Scholar
  21. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130:1552–65.PubMedCrossRefGoogle Scholar
  22. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care. 1999;8:219–27.PubMedCentralPubMedCrossRefGoogle Scholar
  23. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–44.PubMedCrossRefGoogle Scholar
  24. Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, McCrone P, et al. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One. 2012;7:e46327.PubMedCentralPubMedCrossRefGoogle Scholar
  25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.PubMedCrossRefGoogle Scholar
  26. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RHS, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology. 2000;54:1596–602.PubMedCrossRefGoogle Scholar
  27. Kaur B, Harvey DJ, Decarli CS, Zhang L, Sabbagh MN, Olichney JM. Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies. Alzheimer Dis Assoc Disord. 2013;27(3):226–32. doi: 10.1097/WAD.0b013e31826f040d.PubMedCrossRefGoogle Scholar
  28. Kim SH, Seo SW, Go SM, Chin J, Lee BH, Lee JH, et al. Pyramidal and extrapyramidal scale (PEPS): a new scale for the assessment of motor impairment in vascular cognitive impairment associated with small vessel disease. Nab Clin Neurol Neurosurg. 2011a;113:181–7.CrossRefGoogle Scholar
  29. Kim SH, Park JS, Ahn HJ, Seo SW, Lee JM, Kim ST, et al. Voxel-based analysis of diffusion tensor imaging in patients with subcortical vascular cognitive impairment: correlates with cognitive and motor deficits. J Neuroimaging. 2011b;21:317–24.PubMedCrossRefGoogle Scholar
  30. Knol W, Keijsers CJ, Jansen PA, van Marum RJ. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol. 2010;30:57–63.PubMedCrossRefGoogle Scholar
  31. Krismer F, Seppi K, Tison F, Sampaio C, Zangerl A, Peralta C, et al. The unified multiple system atrophy rating scale: intrarater reliability. Mov Disord. 2012;27:1683–5.PubMedCrossRefGoogle Scholar
  32. Kroonenberg PM, Oort FJ, Stebbins GT, Leurgans SE, Cubo E, Goetz CG. Motor function in Parkinson’s disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006;6:26.PubMedCentralPubMedCrossRefGoogle Scholar
  33. Louis ED, Tang MX, Schupf N. Mild parkinsonian signs are associated with increased risk of dementia in a prospective, population-based study of elders. Mov Disord. 2010;25:172–8.PubMedCentralPubMedCrossRefGoogle Scholar
  34. Marinus J, Visser M, Stiggelbout AM, Martin Rabey J, Martinez-Martin P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry. 2004;75:388–95.PubMedCentralPubMedCrossRefGoogle Scholar
  35. Martinez-Martin P, Forjaz MJ. Metric attributes of the unified Parkinson’s disease rating scale 3.0 battery: part I, feasibility, scaling assumptions, reliability, and precision. Mov Disord. 2006;21:1182–8.PubMedCrossRefGoogle Scholar
  36. Martinez-Martin P, Benito-Leon J, Burguera JA, Castro A, Linazasoro G, Martinez-Castrillo JC, et al. The SCOPA-motor scale for assessment of Parkinson’s disease is a consistent and valid measure. J Clin Epidemiol. 2005;58:674–9.PubMedCrossRefGoogle Scholar
  37. Martinez-Martin P, Osa Ruiz E, Gómez-Conesa A, Olazarán J, The RSGE-CD Validation Group. A Rating Scale for Gait Evaluation in Cognitive Deterioration (RSGE-CD): validation study. J Alzheimers Dis. 2012;31:543–53.PubMedGoogle Scholar
  38. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol. 2013;260:228–36.PubMedCrossRefGoogle Scholar
  39. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453–61.PubMedCrossRefGoogle Scholar
  40. McKeith IG, Rowan E, Askew K, Naidu A, Allan L, Barnett N, et al. More severe functional impairment in dementia with Lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry. 2006;14:582–8.PubMedCrossRefGoogle Scholar
  41. Merello M, Gerschcovich ER, Ballesteros D, Cerquetti D. Correlation between the Movement Disorders Society Unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during l-dopa acute challenge. Parkinsonism Relat Disord. 2011;17:705–7.PubMedCrossRefGoogle Scholar
  42. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50.CrossRefGoogle Scholar
  43. Müller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, et al. β-amyloid and postural instability and gait difficulty in Parkinson’s disease at risk for dementia. Mov Disord. 2013;28:296–301.PubMedCentralPubMedCrossRefGoogle Scholar
  44. Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 2012;12:131.PubMedCentralPubMedCrossRefGoogle Scholar
  45. Pal G, Goetz CG. Assessing bradykinesia in Parkinsonian disorders. Front Neurol. 2013;4:54.PubMedCentralPubMedCrossRefGoogle Scholar
  46. Park M, Comella CL, Leurgans SE, Fan W, Wilson RS, Bennett DA. Association of daytime napping and Parkinsonian signs in Alzheimer’s disease. Sleep Med. 2006;7:614–8.PubMedCrossRefGoogle Scholar
  47. Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson Plus Scale. PLoS One. 2011;6:e22293.PubMedCentralPubMedCrossRefGoogle Scholar
  48. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70:580–6.Google Scholar
  49. Ramaker C, Marinus J, Stiggelbout AM, van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17:867–76.PubMedCrossRefGoogle Scholar
  50. Ramirez Diaz SP, Gil Gregorio P, Ribera Casado JM, Reynish E, Ousset PJ, Vellas B, et al. The need for a consensus in the use of assessment tools for Alzheimer’s disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer’s Disease Consortium’s (EADC) survey. Int J Geriatr Psychiatry. 2005;20:744–8.CrossRefGoogle Scholar
  51. Reid WGJ, Broe GA, Hely MA, Morris JG, Williamson PM, O’Sullivan DJ, et al. The neuropsychology of de novo patients with idiopathic Parkinson’s disease: the effects of age of onset. Int J Neurosci. 1989;48:205–17.PubMedCrossRefGoogle Scholar
  52. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24(4):653–9.PubMedGoogle Scholar
  53. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies. Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3, CD006504.PubMedGoogle Scholar
  54. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23:295–7.PubMedCentralPubMedCrossRefGoogle Scholar
  55. Seppi K, Yekhlef F, Diem A, Luginger Wolf E, Mueller J, Tison F, et al. Progression of parkinsonism in multiple system atrophy. J Neurol. 2005;252:91–6.PubMedCrossRefGoogle Scholar
  56. Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, et al. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson’s disease. Mov Disord. 2002a;17:701–9.PubMedCrossRefGoogle Scholar
  57. Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning GK, et al. Application of the international cooperative ataxia scale rating in multiple system atrophy. Mov Disord. 2002b;17:1248–54.PubMedCrossRefGoogle Scholar
  58. Webster DD. Critical analysis of the disability in Parkinson’s disease. Mod Treat. 1968;5:257–82.PubMedGoogle Scholar
  59. Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391–402.PubMedCrossRefGoogle Scholar
  60. Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12:264–74.PubMedCentralPubMedCrossRefGoogle Scholar
  61. Whitwell JL, Master AV, Avula R, Kantarci K, Eggers SD, Edmonson HA, Jack Jr CR, Josephs KA. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol. 2011;68:753–60.PubMedCentralPubMedCrossRefGoogle Scholar
  62. Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67:1935–41.PubMedCrossRefGoogle Scholar
  63. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonian signs in Alzheimer’s disease. Neurology. 2000;54:1284–9.PubMedCrossRefGoogle Scholar
  64. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21:343–54.PubMedCrossRefGoogle Scholar
  65. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Carmen Rodriguez-Blazquez
    • 4
  • Anna Sauerbier
    • 1
    • 2
    • 3
  • K. Ray Chaudhuri
    • 1
    • 2
    • 3
  • Pablo Martinez-Martin
    • 5
    Email author
  1. 1.National Parkinson Foundation International Centre of Excellence, King’s College LondonLondonUK
  2. 2.National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South LondonLondonUK
  3. 3.Department of NeurologyMaudsley NHS Foundation TrustLondonUK
  4. 4.Department of Applied EpidemiologyNational Centre of Epidemiology and Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Carlos III Institute of HealthMadridSpain
  5. 5.Research UnitAlzheimer Centre Reina Sofi a Foundation and Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), CIEN-Foundation, Carlos III Institute of HealthMadridSpain

Personalised recommendations